Compare BridgeBio Pharma Inc (BBIO) vs Endeavour Silver Corp (EXK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Endeavour Silver Corp — how do they compare? BridgeBio Pharma Inc trades at $84.12 (market cap $16.46B), while Endeavour Silver Corp trades at $8.01 (market cap $2.39B). The key difference: BridgeBio Pharma Inc is far larger — about 6.9× Endeavour Silver Corp's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Endeavour Silver Corp nearer its low. Which is the better fit depends on your goals.
| BBIO | EXK | |
|---|---|---|
Market Cap | $16.46B | $2.39B |
Sector | Health | Basic Materials |
52-Week High | $90.17 | $14.12 |
52-Week Low | $44.81 | $4.96 |
Enterprise Value | $18.02B | $2.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
EXK trades at $7.84, down 2.97% on the day, amid a bearish technical signal. The company reported strong Q1 2026 results with earnings of $0.21 per share beating estimates, driven by record production. However, full-year 2025 financials show a net loss of $119.10 million. Analyst sentiment is largely positive with 11 buy ratings, but the stock faces headwinds from negative profitability metrics and high valuation multiples.
The outlook is mixed; operational improvements and silver price trends offer upside, but persistent losses and bearish technicals pose risks. Investors should weigh the company's growth potential against its current financial health and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →
